Clinical studies
Tomorrow's therapies come from today's studies!
We offer a wide range of services from early clinical trials (phase I, first-in-human) to large randomized phase III trials, as well as phase IV and registry studies. We are currently conducting more than 70 clinical trials in oncology, of which an average of 30 are actively recruiting studies. The portfolio includes trials for all solid tumors and lymphomas, in both early and advanced tumor stages.
The team, headed by Prof. Heinz Läubli, Dr. David König and Céline Jenni, comprises 12 employees and is part of the Oncology Department at the University Hospital Basel. This gives patients access to new therapeutic approaches in order to achieve optimal oncological treatment.
If you, as a referring physician or patient, have any questions about a study or possible participation in a study, please send an e-mail to the contact person provided.
Gastrointestinal tumors
Brain tumors
Glioblastoma
GLUGLIO
A phase IB/II study of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma.
Contact person: Prof. Heinz Läubli
GLIOSUN
A study to evaluate the safety and efficacy of the anti-tumor human antibody cytokine fusion protein L19TNF in combination with standard chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma.
Contact person: Dr. Benjamin Thiele
Lung tumors
Small cell lung cancer (SCLC)
ETOP 23-22 RAISE
A phase II study to investigate the effect of niraparib and immunotherapy in patients with SLFN11-positive small cell lung cancer.
Contact person: Dr. David König
DeLLphi-305
A phase III study of tarlatamab in combination with durvalumab versus durvalumab alone in patients with advanced-stage small cell lung cancer after prior chemoimmunotherapy.
Contact person: Dr. Andreas Schmitt
Non-small cell lung cancer (NSCLC)
ETOP 25-23 ADOPT
A phase III study to evaluate the benefit of adjuvant durvalumab treatment after neoadjuvant chemotherapy plus durvalumab in patients with operable stage IIB-IIIB (N2) non-small cell lung cancer.
Contact person: Dr. David König
SGNB6A-002
A phase III study of sigvotatug vedotin versus docetaxel in pretreated non-small cell lung cancer.
Contact person: Dr. Andreas Schmitt
SAKK 16/18
A phase II trial in which radiotherapy is used to enhance the effect of pre-operative (before tumor surgery) immunotherapy in patients with locally advanced non-small cell lung cancer.
Contact person: Dr. David König
PACIFIC-8
A phase III study of durvalumab in combination with domvanalimab versus durvalumab and placebo in patients with locally advanced (stage III), inoperable non-small cell lung cancer whose disease has not progressed after definitive platinum-based radiochemotherapy.
Contact person: Dr. David König
TROPION-Lung 08
A phase III study of Dato-DXd plus pembrolizumab compared to pembrolizumab alone in untreated study participants with advanced or metastatic non-small cell lung cancer with high PD-L1 levels (≥ 50%), without targetable genomic alterations.
Contact person: Dr. Benjamin Thiele
Krascendo 170 Lung
A Phase IB/II study to evaluate the safety and efficacy of GDC-6036 at various doses in combination with other cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRASG12C mutation.
Contact person: Dr. David König
CodeBreak 202
A phase III study of first-line treatment with platinum chemotherapy in combination with sotorasib versus pembrolizumab in PD-L1-negative and KRASG12C-positive advanced/metastatic non-small cell lung cancer.
Contact person: PD Dr. Benjamin Kasenda
BaseTIL-02
A phase II trial of adoptive cell therapy with tumor-infiltrating lymphocytes in patients with non-small cell lung cancer.
Contact person: Dr. David König
Lymphomas (non-Hodgkin's)
General
NX-5948-301
A phase I study to evaluate the safety and efficacy of NX-5948, a Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies.
Contact person: PD Dr. Benjamin Kasenda
CA123-1000
A Phase I/II study of BMS-986458 alone or in combination with anti-lymphoma agents in relapsed/refractory non-Hodgkin lymphoma.
Contact person: Dr. Fatime Krasniqi
SAKK 38/23 LIBERTY
Liquid biopsy for the diagnosis and monitoring of central nervous system involvement in patients with high-risk B-cell non-Hodgkin's lymphoma.
Contact person: PD Dr. Benjamin Kasenda
Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma
OLYMPIA-1
A phase III study to compare the efficacy and safety of odronextamab versus standard therapy in previously untreated participants with follicular lymphoma.
Contact person: Dr. Fatime Krasniqi
Melanomas
BaseTIL-03
A phase I study on tumor treatment with autologous immune cells and ANV419 in patients with advanced melanoma.
Contact person: Prof. Heinz Läubli
Mesothelioma
eVOLVE-Meso
A phase III study with Volrustomig in combination with chemotherapy compared to chemotherapy alone in inoperable pleural mesothelioma.
Contact person: Dr. David König
Sarcomas
SaLuDo
A phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.
Contact person: Dr. Fatime Krasniqi
Urogenital tumors
Bladder cancer
SAKK 06/19
A phase II study of intravesical BCG followed by chemoimmunotherapy in patients with operable, muscle-invasive bladder cancer.
Contact person: Prof. Frank Stenner
Prostate cancer
ProBio
An outcome-adaptive study with biomarkers in patients with metastatic prostate cancer.
Contact person: Prof. Frank Stenner
Various tumors / Phase I studies
DODEKA
A Phase I study to assess the safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Contact person: Dr. David König
IMC-F106C-101
A Phase I/II study of the safety and efficacy of IMC-F106C as a single agent and in combination with immunotherapy in HLA-A*02:01-positive participants with advanced PRAME-positive cancers.
Contact person: Dr. Anton Oseledchyk
ISCA-CHECK
Safety and modulation of adaptive immunity by Iscador® Qu Viscum Album extract in patients with advanced, recurrent or metastatic cancer treated with immune checkpoint inhibitors.
Contact person: Prof. Mascha Binder